The National Cancer Institute (NCI) and the Avon Foundation announced today initial grant awards to six applicants for the Avon-NCI "Progress for Patients" Awards Program. These grants, which total $2.5 million, are the first awarded from the unique public-private partnership between the Avon Foundation and NCI, and they encompass all areas of clinical investigation important to breast cancer, including prevention, detection, diagnosis, prediction, prognosis and treatment. The awards will help fund innovative translational science at 10 research institutions. Funding will support early clinical research in breast cancer, including the use of aromatase inhibitors as a prevention tool, new methods of radioimmunotherapy for women with metastatic disease, as well as other areas of research.
The Progress for Patients program was launched in October 2001 when the NCI received a $20 million pledge from the Avon Foundation to fund translational research on breast cancer. The pledge is Avon's largest single award ever. The funds were raised by the Avon Breast Cancer Crusade, which has generated more than $200 million in the Unites States alone from 1993 to mid-year 2002. Avon is one of the world's leading corporate supporters of the breast cancer cause, with programs in nearly 50 countries, and the only one to fund the whole spectrum of the breast cancer cause - medical research, clinical care, support services, education and early detection - with a focus on medically underserved women.
Applicants for the Progress for Patients grants were encouraged to include minorities and underserved women in their studies. According to Jorge Gomez, M.D., NCI, "the breadth of projects that we recommended for funding was truly impressive, which made choosing the final grant awardees a very difficult, but rewarding process."
Nine applications for the grants were received from the SPORE (Specialized Programs of Research Excellence) program, which target all tyPage: 1 2 3 Related medicine news :1
Contact: NCI Press Office
NIH/National Cancer Institute
. Initial findings of first comprehensive study into ageing process published2
. Initially recommended drug dosages often too high, study finds3
. Initial chemotherapy treatment reduces relapses in MS patients4
. Initial clinical study shows safety and bioactivity of cancer vaccine5
. International breast cancer prevention study launches in the United States and Canada6
. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo7
. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds8
. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased9
. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women10
. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans11
. Postmenopausal breast cancer survivors at increased risk for bone fractures